Phase 1 clinical trials evaluate the safety and dosage of proposed new treatments. Further research is needed to test the oncolytic virus therapy’s effectiveness and side effects. Work also continues ...

Glioblastoma is the most aggressive and deadliest form of brain cancer. Most patients survive only about a year after diagnosis, and just 5% make it to five years. Dr. Minesh P. Mehta is leading the ...

The blood–brain barrier functions as an evolutionarily optimized vascular “filter,” permitting limited penetration of small molecules like temozolomide while effectively excluding most biologics from ...

A 43-year-old UK father shows no signs of having a brain tumor -- he took an immunotherapy drug before his glioblastoma treatment. A breakthrough drug is fighting brain cancer head-on. Glioblastoma is ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this aggressive tumor permanently disappear. The tumor cells are too varied, and the ...

In a surprising and hopeful turn of events, a 40-year-old father is living his best life in his second innings, after he was diagnosed with terminal glioblastoma in 2023. In fact, three years later, ...

Researchers have uncovered new targets that could be the key to effectively treating glioblastoma, a lethal type of brain cancer. These targets were identified through a screen for genetic ...

MT-125, a selective inhibitor of non-muscle myosin II, targets glioblastoma's tumor proliferation and resistance mechanisms. The FDA's fast track designation aims to expedite MT-125's development and ...

Add Yahoo as a preferred source to see more of our stories on Google. A 43-year-old UK father shows no signs of having a brain tumor -- he took an immunotherapy drug before his glioblastoma treatment.

A breakthrough drug is fighting brain cancer head-on. Glioblastoma is widely considered the deadliest form of brain cancer, killing over 10,000 Americans each year. There is no cure for the highly ...